Why Is DexCom (DXCM) In Focus After Its G7 Trial Reached NEJM?

DexCom (NasdaqGS:DXCM) reported that results from the CONNECT randomized controlled trial of its G7 CGM were published in The ...

DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives

DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence. Read why DXCM stock is a Buy.
MobiHealthNews

Dexcom discovers two lots of stolen G7 sensors being sold to the public

Editor's note: This article has been updated with a comment from a Pharmsource spokesperson. Continuous glucose monitoring specialist Dexcom has identified two lots of Dexcom G7 sensors (1725204004 ...
MobiHealthNews

Dexcom receives FDA clearance for G7 15 Day glucose monitoring system

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...
24/7 Wall St.

Dexcom Q3 2026: Raised Guidance and a $1 Billion Buyback

Dexcom raised full-year revenue guidance again, to $5.20 billion to $5.25 billion, after topping expectations on both lines.

What to expect from DexCom’s (DXCM) Q3 earnings

Medical device company DexCom (NASDAQ:DXCM) will be reporting results this Thursday after the bell. Here’s what investors ...
Seeking Alpha

DexCom's Competitive Landscape: A Deep Dive Into The CGM Market

DexCom, Inc. reduced its 2024 revenue guidance following a decline in new U.S. customers and revenue per customer, leading to a sharp share price drop, despite $750 million share buyback. DexCom faces ...
Business Wire

Dexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S.

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the FDA has cleared the next-generation ...